CRM and the Drugs for Neglected Diseases initiative Signed Agreement to Launch Clinical Studies for a Public Health Approach to Hepatitis C in Malaysia
[Putrajaya, 13 January 2016] The Drugs for Neglected Diseases initiative (DNDi) and the Ministry of Health of the Government of Malaysia have agreed to work together to develop a public health approach to Hepatitis C within the framework of the future National Strategic Plan on viral hepatitis. The immediate goal is to conduct clinical studies of promising new treatment regimens for Hepatitis C, to be followed by scale-up of treatment for patients, with the overall objective of ensuring equitable access to affordable and effective treatments for patients suffering from this disease in Malaysia.
Health Minister Datuk Seri Dr S. Subramaniam (centre) witnessing the exchanging of a memorandum of understanding between Clinical Research Malaysia chief executive officer Dr Akhmal Yusof (right) and Drugs for Neglected Diseases initiative Head of Paediatrics HIV Programme Dr Marc Lallemont
The clinical studies will be launched later this year in multiple sites, with DNDi and Clinical Research Malaysia (CRM), a non-profit company owned by the Ministry of Health, as the co-sponsors.
